Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives

References

• CDCgov [homepage on the internet]NCHS Data Brief: Leading Causes of Death 2013 (Number 64): United States. Centers of Disease Control and Prevention2013 Available from: http://cdc.gov/Accessed January 5, 2016
   Google Scholar
• MichaJPRettenmaierMABrownJV3rdA randomized controlled pilot study comparing the impact of aprepitant and fosaprepitant on chemotherapy induced nausea and vomiting in patients treated for gynecologic cancerInt J Gynecol Cancer201626238939326588232
   PubMed Web of Science ®Google Scholar
• MoradianSHowellDPrevention and management of chemotherapy-induced nausea and vomitingInt J Palliat Nurs201521521626107543
   PubMedGoogle Scholar
• AyersMOloweOA systematic review: non pharmacologic interventions for chemotherapy induced nausea and vomitingHonors Research Projects Paper 1102015
   Google Scholar
• SchwartzbergLSRugoHSAaproMSNew and emerging therapeutic options for the management of chemotherapy-induced nausea and vomitingClin Adv Hematol Oncol2015133 Suppl 3313125856052
   PubMedGoogle Scholar
• BaschEPrestrudAAHeskethPJAmerican Society of Clinical OncologyAntiemetics: American Society of Clinical Oncology clinical practice guideline updateJ Clin Oncol201129314189419821947834
   PubMed Web of Science ®Google Scholar
• ErratumJ Clin Oncol201432192117
   Web of Science ®Google Scholar
• JanelsinsMCTejaniMAKamenCPeoplesARMustianKMMorrowGRCurrent pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patientsExpert Opin Pharmacother201314675776623496347
   PubMed Web of Science ®Google Scholar
• KamenCTejaniMAChandwaniKAnticipatory nausea and vomiting due to chemotherapyEur J Pharmacol201472217217924157982
   PubMed Web of Science ®Google Scholar
• BlackshawLABrookesSJGrundyDSchemannMSensory transmission in the gastrointestinal tractNeurogastroenterol Motil2007191 Suppl11917280582
   PubMed Web of Science ®Google Scholar
• BerthoudHRBlackshawLABrookesSJGrundyDNeuroanatomy of extrinsic afferents supplying the gastrointestinal tractNeurogastroenterol Motil200416Suppl 1283315066001
   PubMed Web of Science ®Google Scholar
• GrundyDWhat activates visceral afferents?Gut200453Suppl 2ii5ii814960550
   PubMed Web of Science ®Google Scholar
• GrundyD5-HT system in the gut: roles in the regulation of visceral sensitivity and motor functionsEur Rev Med Pharmacol Sci200812Suppl 1636718924445
   PubMed Web of Science ®Google Scholar
• AndrewsPLRRuddJAThe role of tachykinins and the tachykinin K receptor in nausea and emesisHandbook of Experimental Pharmacology164Berlin, GermanySpringer-Verlag2004359440
   Google Scholar
• Garcia-RecioSGascónPBiological and pharmacological aspects of the NK1-receptorBiomed Res Int2015201549570426421291
   PubMed Web of Science ®Google Scholar
• SchnellFMChemotherapy-induced nausea and vomiting: the importance of acute antiemetic controlOncologist20038218719812697943
   PubMed Web of Science ®Google Scholar
• SekineISegawaYKubotaKSaekiTRisk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxisCancer Sci2013104671171723480814
   PubMed Web of Science ®Google Scholar
• OsobaDZeeBPaterJWarrDLatreilleJKaizerLDeterminants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials GroupJ Clin Oncol19971511161238996132
   PubMed Web of Science ®Google Scholar
• HeskethPJChemotherapy-induced nausea and vomitingN Engl J Med2008358232482249418525044
   PubMed Web of Science ®Google Scholar
• CohenLde MoorCAEisenbergPMingEEHuHChemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settingsSupport Care Cancer200715549750317103197
   PubMed Web of Science ®Google Scholar
• Colon-GonzalezFKraftWKPharmacokinetic evaluation of fosaprepitant dimeglumineExpert Opin Drug Metab Toxicol20106101277128620795794
   PubMed Web of Science ®Google Scholar
• CelioLRicchiniFDe BraudFSafety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomitingPatient Prefer Adherence2013739140023687442
   PubMed Web of Science ®Google Scholar
• DushenkoyAKalabalikJCarboneAJungsuwadeePDrug interactions with aprepitant or fosaprepitant: review of literature and implications for clinical practiceJ Oncol Pharm Pract Epub2252016
   Web of Science ®Google Scholar
• GrunbergSChuaDMaruASingle-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol – EASEJ Clin Oncol201129111495150121383291
   PubMed Web of Science ®Google Scholar
• AndoYHayashiTItoKComparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapySupport Care Cancer201624287187826206077
   PubMed Web of Science ®Google Scholar
• SaitoHYoshizawaHYoshimoriKEfficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trialAnn Oncol20132441067107323117073
   PubMed Web of Science ®Google Scholar
• WeinsteinCJordanKGreenSASingle-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trialAnn Oncol201627117217826449391
   PubMed Web of Science ®Google Scholar
• NishimuraJSatohTFukunagaMMulti-center Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO)Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trialEur J Cancer201551101274128225922233
   PubMed Web of Science ®Google Scholar
• KitayamaHTsujiYSugiyamaJDoiAKondoTHirayamaMEfficacy of palonosetron and 1-day dexamethasone in moderately emetogenic chemotherapy compared with fosaprepitant, granisetron, and dexamethasone: a prospective randomized crossover studyInt J Clin Oncol20152061051105625822106
   PubMed Web of Science ®Google Scholar
• HegerovaLTLealADGrendahlDCAn analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapySupport Care Cancer2015231555924964876
   PubMed Web of Science ®Google Scholar
• SatoYKondoMInagakiAHighly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patientsJ Cancer20145539039724799957
   PubMed Web of Science ®Google Scholar
• FujiiTNishimuraNUrayamaKYDifferential impact of fosaprepitant on infusion site adverse events between cisplatin- and anthracycline-based chemotherapy regimensAnticancer Res201535137938325550575
   PubMed Web of Science ®Google Scholar
• LealADKadakiaKCLookerSFosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapySupport Care Cancer20142251313131724402411
   PubMed Web of Science ®Google Scholar
• ChowAYChinCDahlGRosenthalDNAnthracyclines cause endothelial injury in pediatric cancer patients: a pilot studyJ Clin Oncol200624692592816484703
   PubMed Web of Science ®Google Scholar
• LundbergJDCrawfordBSPhillipsGBergerMJWesolowskiRIncidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitantSupport Care Cancer20142261461146624402412
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for NCCN Guidelines for Antiemesis V.2.2016 Available from: https://www.nccn.org/professionals/physician_gls/f_guidelines.aspAccessed March 31, 2016
   Google Scholar
• RoilaFHerrstedtJAaproMESMO/MASCC Guidelines Working GroupGuideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conferenceAnn Oncol201021Suppl 5v232v24320555089
   PubMed Web of Science ®Google Scholar